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Abstract
Purpose: The aim of this work was to use a multi-center audit of modulated radiotherapy quality
assurance (QA) data to provide a practical examination of gamma evaluation criteria and action
level selection. The use of the gamma evaluation method for patient-specific pre-treatment QA is
widespread, with most commercial solutions implementing the method.
Methods: Gamma agreement indices were calculated using the criteria 1%/1mm, 2%/2mm,
2%/3mm, 3%/2mm, 3%/3mm and 5%/3mm for 1265 pre-treatment QA measurements, planned
at 7 treatment centers, using 4 different treatment planning systems, delivered using 3 different
delivery systems (intensity-modulated radiation therapy (IMRT), volumetric-modulated arc ther-
apy (VMAT) and helical tomotherapy (HT)) and measured using 3 different dose measurement
systems. The sensitivity of each gamma criteria was evaluated relative to the gamma agreement
indices calculated using 3%/3mm.
Results: A linear relationship was observed for 2%/2mm, 2%/3mm and 3%/2mm. This result
implies that most beams failing at 3%/3mm would also fail for those criteria, if the action level
was adjusted appropriately. Some borderline plans might be passed or failed depending on the
relative priority (tighter tolerance) used for dose difference or distance to agreement evaluation.
Dosimeter resolution and treatment modality were found to have a smaller effect on the results of
QA measurements than the number of dimensions (2D or 3D) over which the gamma evaluation
was calculated.
Conclusions: This work provides a method (and a large sample of results) for calculating
equivalent action levels for different gamma evaluation criteria. This work constitutes a valuable
guide for clinical decision making and a means to compare published gamma evaluation results
from studies using different evaluation criteria. More generally, the data provided by this work
support the recommendation that gamma criteria that specifically prioritize the property of
greatest clinical importance for each treatment modality of anatomical site should be selected
when using gamma evaluations for modulated radiotherapy QA. It is therefore suggested that
departments using the gamma evaluation as a QA analysis tool should consider the relative
importance of dose difference and distance to agreement, when selecting gamma evaluation criteria.
∗ Email: sb.crowe@gmail.com; Website: http://sbcrowe.net
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I. INTRODUCTION
The verification of modulated radiotherapy treatment delivery, including intensity modu-
lated radiotherapy (IMRT) and volumetric arc radiotherapy (VMAT), using patient specific
pre-treatment quality assurance (QA) measurements has been recommended as an essen-
tial part of the treatment delivery chain [1]. The verification of treatment deliverability5
has become increasingly important with the widespread adoption of modulated treatment
techniques for treatments of a variety of anatomical sites [2–4].
Modulated radiotherapy treatment plans can be verified in a variety of ways including the
use of: dosimetric film [5], two- and three-dimensional arrays of diodes [6–8], and integrated
images of the treatment beams acquired with the linac’s built-in electronic portal imaging10
device (EPID) [9–11] or exit detector [12]. Such QA testing typically involves a comparison
between predicted and measured doses using a gamma evaluation [13].
The gamma (γ) evaluation comparison method allows the evaluation of agreement be-
tween two dose distributions (either 2D or 3D) in a combined dose-spatial domain. For every
dose point in the evaluation distribution, the nearest (both in terms of dose and space) dose15
point in the reference distribution is determined, and the agreement is tested against two
criteria: a dose-difference (∆D, a percentage of either the global maximum dose, or the
local dose) and a distance-to-agreement (DTA, measured in mm). The method is useful for
comparing distributions that feature steep dose gradients [13], where small displacements
can result in substantial changes in dose.20
The result of a γ evaluation is a distribution of γ values, where γ ≤ unity indicates
agreement within the two criteria. The percentage of dose points in agreement can be
referred to as the γ agreement index (GAI). The entire distribution of γ values is generally
not considered when calculating the GAI - typically only values in the region of interest or
values corresponding to a dose exceeding a user-defined lower dose threshold (e.g. 10% of25
maximum dose) are considered. GAI values are then evaluated against clinical action levels,
to establish confidence in the deliverability of the treatment.
Studies have suggested that GAI analysis of planar dose measurements are a poor indica-
tor of clinically meaningful dose delivery errors [14–16]. Despite this, the use of γ evaluations
in pre-treatment quality assurance is widespread. Support is implemented in most, if not30
all, commercial QA solutions, including the SNC Patient software (Sun Nuclear, Melbourne,
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USA), Varian Portal Dosimetry (Varian Medical Systems, Palo Alto, USA), VeriSoft Patient
Plan Verification (PTW-Freiburg, Freiburg, Germany), FilmQA Pro (Ashland Inc, Wayne,
USA) and Epiqa (EPIdos, Bratislava, Slovakia). A study by Eaton [17] reported that the
original γ evaluation paper by Low et al. [18] received the 5th highest number of citations35
per year (42.5) of all papers published in Medical Physics.
The ∆D and DTA criteria of 3%/3mm have remained widely used since the introduction
of the γ evaluation method by Low et al. [18]. A 2007 survey by Nelms & Simon [19] found
76.3% of respondents used 3% as their standard ∆D, and 82.7% of respondents used 3mm
as their standard DTA. Nelms et al. [20] have suggested the retirement of 3%/3mm and the40
adoption of tighter tolerances.
Previous studies have investigated the effect of detector selection [11, 27, 28] and the effect
of γ criteria selection [29–31] on measured GAI values, producing a variety of results, but
there are few recommendations on how to use such information clinically for the selection
of γ criteria or action levels. The report of the AAPM Task Group 119 [21] used confidence45
limits on measurement accuracy to recommend action levels of 88%-90% (with a 10% lower
dose threshold) for radiochromic film. Vinall et al. [22], looking at the number of pixels with
γ ≥ 1, selected action level based on observations of where tongue and groove effects became
visible. Howell et al. [23] identified outliers where the difference between the γ results and
the institutional mean differed by an amount greater than the standard deviation of that50
mean. Evidently, the selection of an action level should be dependent on the sensitivity of
the γ analysis to measured errors in delivery.
In this study, a multi-center audit of QA data was undertaken in order to evaluate the
effects of using various γ criteria for a large number of clinical radiotherapy treatment plans
measured using some contemporary dosimetry systems. This study therefore systematically55
re-evaluated QA measurements of IMRT, VMAT and helical tomotherapy (HT) beams de-
livered at seven treatment centers and discusses the selection of action levels based on the
resulting data. The information provided in this note may be used to inform clinical decision
making around QA practices and γ evaluation criteria and action levels in the future.
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II. MATERIALS AND METHODS60
This study examined the results of 1,265 pre-treatment QA measurements for clinically
planned treatments from seven radiation oncology providers who used nine different treat-
ment and dosimeter combinations. The relevant properties (treatment modality, treatment
planning system (TPS) and QA system) of the nine sets of beams are listed in table I.
For each set, GAI values were calculated using six pairs of γ criteria; 1%/1mm, 2%/2mm,65
2%/3mm, 3%/2mm, 3%/3mm and 5%/3mm. Evaluation parameters included: a lower dose
threshold of 5% (to mitigate effects of region of interest selection), a global normalisation
of percent dose difference (to the maximum dose), and dose interpolation avoided where
possible. Absolute dose values were used, where possible, otherwise dose was normalised to
the maximum value in the planned distribution.70
For each set of QA results evaluated the mean GAI (and standard deviation in the mean)
were calculated. The results of using 3%/3mm γ criteria were taken as the baseline, and
ordinary least squares regression was used to quantify the relationships between this baseline
data and the results of using the other pairs of criteria. The results of linear regression were
used to find clinically equivalent GAIs for γ criteria other than 3%/3mm; specifically, values75
equivalent to the commonly used 90% action level. These results were weighted by the
number of beams in each set, listed in table I.
All of the QA systems used by the centers participating in this study (see table I) have
been described and examined in previous studies. Specifically, The Epiqa system and its use
in obtaining QA measurements from high-resolution EPID images has been described by80
Nicolini et al. [10]. The two-dimensional planar MapCheck2 diode array has been described
and investigated by Jursinic et al [6, 24]. The cylindrical ArcCheck diode array and its
use for producing three-dimensional dose measurements and performing three-dimensional
gamma evaluations has been described by Li et al [7] and applied to TomoTherapy treatment
QA by Binny et al [26]. The SNC Patient Software is a more recent version of the MapCheck85
software. Some of the data used in this study (in sets a, c and d) have also been used in
previous IMRT and VMAT plan complexity studies [31, 32].
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TABLE I. Description of treatment modalities, number of beams, treatment planning systems,
measurement device and QA software used for each set of beams.
Set Modality Beams TPS Algorithm Accelerator MLC Dosimeter Software
a IMRT 402 Eclipse v11 AAA Varian 21iX Millennium aS1000 EPID Epiqa
b IMRT 128 Eclipse v9 AAA Varian 21iX Millennium MapCheck2 MapCheck
c IMRT 107 Eclipse v13.5 AAA Varian 21iX Millennium MapCheck2 SNC Patient
d IMRT 150 iPlan v4.5 PBC Varian 21iX Brainlab m3 MapCheck2 MapCheck
e VMAT 148 Eclipse v11 AAA Varian 21iX Millennium aS1000 EPID Epiqa
f VMAT 85 Eclipse v9 AAA Varian 21iX Millennium MapCheck2 MapCheck
g VMAT 50 Eclipse v13.5 AAA Varian 21iX Millennium ArcCheck SNC Patient
h VMAT 109 Pinnacle v9.8 CCC Elekta Agility ArcCheck SNC Patient
i HT 86 Hi-Art II CCC TomoTherapy binary MLC ArcCheck SNC Patient
III. RESULTS AND DISCUSSION
The mean GAIs for each treatment type and dosimetry system using each acceptance
criteria pair are presented in table II and illustrated (relative to the 3%/3mm baseline) in90
figure 1. These data suggest that the results of the three-dimensional gamma evaluations
provided by the ArcCheck are systematically different from the two-dimensional gamma
evaluations provided by the MapCheck2 and Epiqa systems. Evidently, searching in three
dimensions more easily results in finding a point that agrees within the dose difference
criteria than searching in two dimensions. The MapCheck2 and Epiqa results are similar,95
despite a substantial difference in resolution (from the sub-millimeter resolution of Epiqa to
the approximately 7 mm diode spacing using in the MapCheck2 array).
Figure 2 exemplifies the results of evaluating GAIs using different criteria, for different
treatment and delivery systems. (A complete set of results can be found in supplementary
material [33].) All results show a weak correlation between GAI calculated using 1%/1mm100
and 3%/3mm, that is, that beams with higher GAI calculated at 3%/3mm are not consis-
tently higher when calculated with 1%/1mm. By contrast, the linear correlation between
GAI calculated using 2%/2mm and 3%/3mm is more immediately apparent. A linear cor-
relation between the data obtained at 5%/3mm and 3%/3mm can only be seen where cal-
culated GAI values < 100%. The mean GAI calculated at 5%/3mm was close to 100% for105
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TABLE II. Mean GAI and standard deviation in the mean for each γ criteria pair. Note that the
mean values are weighted by the number of beams in each set, listed in table I.
1%/1mm 2%/2mm 2%/3mm 3%/2mm 3%/3mm 5%/3mm
Set Mean GAI Mean GAI Mean GAI Mean GAI Mean GAI Mean GAI
a (57 ± 8)% (90 ± 5)% (94 ± 4)% (95 ± 3)% (97 ± 2)% (99 ± 1)%
b (56 ± 10)% (87 ± 6)% (95 ± 4)% (91 ± 6)% (97 ± 3)% (99 ± 2)%
c (54 ± 12)% (87 ± 9)% (93 ± 6)% (93 ± 7)% (97 ± 3)% (100 ± 1)%
d (59 ± 10)% (92 ± 6)% (97 ± 3)% (95 ± 6)% (98 ± 3)% (99 ± 3)%
e (55 ± 10)% (88 ± 6)% (93 ± 4)% (93 ± 4)% (96 ± 3)% (98 ± 2)%
f (56 ± 13)% (85 ± 10)% (92 ± 6)% (90 ± 9)% (95 ± 5)% (97 ± 4)%
g (72 ± 13)% (96 ± 4)% (98 ± 2)% (98 ± 2)% (99 ± 1)% (99.9 ± 0.4)%
h (76 ± 10)% (95 ± 5)% (97 ± 3)% (97 ± 3)% (99 ± 2)% (100 ± 1)%
i (61 ± 17)% (91 ± 11)% (95 ± 7)% (96 ± 6)% (98 ± 4)% (99 ± 2)%
All (59 ± 12)% (90 ± 7)% (95 ± 5)% (94 ± 6)% (97 ± 3)% (99 ± 2)%
every set.
The equivalent 1%/1mm, 2%/2mm, 2%/3mm, 3%/2mm and 5%/3mm GAIs for the
commonly used 90% action level at 3%/3mm are presented in table III. If these equivalent
action levels were adopted, the number of beams passing or failing to meet the action level for
the different acceptance criteria would be approximately the same as the number of beams110
passing or failing to meet the 90% action level at 3%/3mm. For acceptance criteria where
GAI values demonstrated a linear relationship with 3%/3mm GAI values (most apparent
with 2%/3mm and 3%/2mm), most of the beams passing or failing to meet the equivalent
action level would also fail to meet the 90% action level at 3%/3mm. The characteristics of
beams that pass at one of these three criteria levels (3%/3mm, 2%/3mm or 3%/2mm) and115
fail at the other two could therefore inform the selection of the γ evaluation criteria to use
clinically, depending on whether the treatment center (or the treatment technique) requires
geometric accuracy to be prioritised above dosimetric accuracy.
The use of 2%/2mm, 2%/3mm and 3%/2mm criteria seems reasonable for the examined
systems, especially if centers are currently using 3%/3mm, given the correlations seen in120
figure 2 and the supplementary material [33]. This assessment agrees with Garcia-Vicente
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FIG. 1. Mean gamma agreement index for each γ criteria pair, normalised to 3%/3mm baseline.
Colour indicates MLC system (Varian M120 blue, Brainlab m3 pink, Elekta Agility green and
Tomotherapy binary MLC orange), line type indicates modality (VMAT solid, IMRT dashed, HT
dotted) and marker type indicates dosimetry system (MapCheck2 square, ArcCheck circular and
Epiqa triangular).
[35], who suggested the use of 3%/2mm with the ArcCheck system after testing sensitivity
to introduced errors, as is suggested by the AAPM Task Group 119 [21].
More generally, the results of the linear regression analysis of the GAI data provided in
this study, or any center’s re-examination of their own QA results, could be used to interpret125
differences in observed GAI between different centers or different publications where different
γ criteria are used.
IV. CONCLUSIONS
The use of a 3%/3mm γ evaluation using a planar (or cylindrical) dose measurement for
QA is widespread, despite concerns about the suitability of γ evaluations, and suggestions130
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FIG. 2. Examples of comparisons between GAI calculated using acceptance criteria of 1%/1mm,
2%/2mm and 5%/3mm, and 3%/3mm for result sets b, e and h (see table I). Solid lines indicate
results of ordinary least squares regression, with gradient and intercept values presented. Full
results are included in supplementary material [33].
that a 3%/3mm evaluation is not sensitive enough. The results of this multi-center audit
suggest that, for the centers examined, the adoption of more sensitive γ criteria, specifically
2%/2mm, 2%/3mm or 3%/2mm could be beneficial. The selection of an appropriate action
9
TABLE III. Equivalent 1%/1mm, 2%/2mm, 2%/3mm, 3%/2mm and 5%/3mm GAI for the com-
monly used 90% at 3%/3mm action level.
1%/1mm 2%/2mm 2%/3mm 3%/2mm 5%/3mm
Set Equivalent Equivalent Equivalent Equivalent Equivalent
a 46% 75% 82% 85% 96%
b 44% 76% 87% 80% 95%
c 36% 68% 81% 79% 99%
d 45% 80% 89% 83% 92%
e 42% 77% 85% 84% 95%
f 47% 77% 87% 82% 94%
g 22% 74% 83% 84% 97%
h 56% 79% 86% 85% 95%
i 42% 74% 82% 85% 96%
All 43% 76% 85% 83% 95%
level could result in only a small change in the number of beams passing QA, despite stricter
discrimination in terms of dose difference or distance to agreement. This study suggests that135
it is possible, and advisable, to select γ criteria that specifically prioritize the property (either
dose difference or distance to agreement) of greatest clinical importance for each treatment
modality or anatomical site while also identifying action levels that maintain acceptable
QA pass rates. More generally, the equivalent action levels, calculated for all pairs of γ
evaluation criteria evaluated in this study, provide a potentially valuable guide for clinical140
decision making and a means to compare between published γ evaluation results from studies
using different evaluation criteria.
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